title: Anti-tumor efficacy and pre-clinical immunogenicity of IFNα2a-NGR.
abstract: Previously studies have shown that tumor-homing peptide NGR enhances the therapeutic efficacy of human interferon α2a (IFNα2a) against tumors. Here we investigated in vivo anti-tumor effect of recombinant human IFNα2a-NGR (rhIFNα2a-NGR) against human lung adenocarcinoma cell line SPC-A-1, A549 and murine Lewis lung carcinoma (LLC) subcutaneously xenografted tumors and further assessed the immunogenicity of rhIFNα2a-NGR in Sprague Dawley (SD) rats and rhesus monkeys. We found that rhIFNα2a-NGR significantly inhibited the growth of SPC-A-1, A549 and LLC cells-xenografted tumors in a dose-dependent manner. Although the antibodies to rhIFNα were detected in the serum of SD rats and rhesus monkeys treated with rhIFNα2a-NGR, these antibodies did not cause obvious pathological consequence. Taken together, these data demonstrate that rhIFNα2a-NGR has obvious anti-tumor efficacy in vivo, perhaps due to the tumor-homing peptide NGR. Thus rhIFNα2a-NGR represents a promising novel drug for effective treatment of cancer.
authors.affiliation: Department of Pharmacology, School of Basic Medical Sciences, Lanzhou University, Lanzhou 730000, China.
authors.forename: Baolai
authors.initials: B
authors.lastname: Zhang
authors.forename: Bei
authors.initials: B
authors.lastname: Gao
authors.forename: Shuhong
authors.initials: S
authors.lastname: Dong
authors.forename: Yingqi
authors.initials: Y
authors.lastname: Zhang
authors.forename: Yongjie
authors.initials: Y
authors.lastname: Wu
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000276:immunology / Q000494:pharmacology*; D045744:Cell Line, Tumor; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000235:genetics* / Q000276:immunology; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000473:pathology; D008253:Macaca mulatta; D051379:Mice; D008807:Mice, Inbred BALB C; D008819:Mice, Nude; D009842:Oligopeptides / Q000235:genetics* / Q000276:immunology; D051381:Rats; D017207:Rats, Sprague-Dawley; D011971:Receptors, Immunologic / Q000235:genetics*; D011993:Recombinant Fusion Proteins / Q000276:immunology / Q000494:pharmacology*; D011994:Recombinant Proteins; D023041:Xenograft Model Antitumor Assays
chemical_list: D000970:Antineoplastic Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; C526428:NGR peptide; D009842:Oligopeptides; D011971:Receptors, Immunologic; D011993:Recombinant Fusion Proteins; D011994:Recombinant Proteins